The Dexcom G6 CGM System.

Technology that lets us manage diabetes without fingersticks.*

* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G6 sensor and app (smart devices sold separately)

Meet the Dexcom G6.

A small, wearable continuously sends glucose readings to your smartphone† or Dexcom receiver - without fingersticks.*

* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Get started with Dexcom G6

Easy to use^‡

The Dexcom G6 is a small, discreet wearable that you apply yourself and lasts up to 10 days.

Goodbye fingersticks^†

Glance at your smartphone.^†See your glucose. Make diabetes treatment decisions. All without fingersticks.*

* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Lowers A1C

Using a Dexcom CGM is proven to lower A1C and help you spend more time in range.^1,2

“I struggled to lower my A1C until I got the Dexcom G6. Now it’s so much easier to stay on top of my glucose. My A1C is down 3 points.”^§

Harrel C., Age 52
Dexcom Warrior
Individual results may vary.

“I want all my Type 2 patients who depend on insulin to be on the Dexcom G6.”

Dr. Michael Heile, T1D
Endocrinologist
Paid spokesperson of Dexcom, Inc.

New Patients: Get Started with Dexcom CGM

Please fill out the form below to help us determine if the Dexcom CGM System is right for you or your loved one. A customer service representative of Dexcom, or a service provider on behalf of Dexcom, may follow up with you to process a full insurance benefits check or to discuss other Dexcom products, services or programs, after reviewing your information.

Personal & Diabetes Information

All fields marked with an asterisk (*) are required.

Personal Information

Are you a current Dexcom CGM user (or have you recently ordered)?

Patient First Name

Patient Last Name

Phone Number

Please enter a valid 10-digit mobile number. Do not include any special characters.

Zip Code

Format: XXXXX-XXXX

City

Gender

Patient Date of Birth

Therapy Coverage Information

Insurance Type

Patient Diabetes Type

Patient Diabetes Therapy

Do you intend to use a Dexcom powered automated insulin delivery (AID) system?

Select One

I agree to Dexcom’s Terms of Use and Privacy Policy, and agree that Dexcom (or a service provider on behalf of Dexcom) may (1) use my information to communicate with me about Dexcom products, services and programs, or to provide me with information relating to my healthcare treatment, payment for healthcare, or other health information or care coordination services, in accordance with such terms; and (2) contact me at the phone number and email address set forth above, and use automatic dialing machines, automated, pre-recorded voice messages, and may send SMS/text messages. I understand that I may opt out at any time by texting “STOP” in return to a text or by calling Dexcom at 888-738-3646, and that my consent to this contact is not required for the purchase of Dexcom products or services. I understand that my service provider’s airtime, message and data rates may apply. In addition, I certify that I (i) am the patient referenced above or (ii) am the parent or legal guardian of the patient referenced above, and that I am at least eighteen (18) years of age. *

I also agree that Dexcom (and a service provider) may share my information with one of Dexcom's distributors that directly serve Medicare beneficiaries.

Have Questions?

Our customer support representatives are available to help answer your questions at 888-738-3646.

* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
† For a list of compatible devices, visit http://www.dexcom.com/compatibility. Stable internet connection required.
‡ See user guide for set up instructions
§ Based upon a customer's experience; individual results may vary. Randomized controlled trial and real-world data indicate that Dexcom CGM use results in a mean A1C reduction of 0.8% (Beck RW et al. Ann Intern Med 2017;167(6):365-74) and 1.5% (Noar A, et al. Presented at ADA 80th Scientific Sessions; June 12, 2020; Virtual) respectively, from baseline for patients with T2D.
1 Beck, RW. JAMA. 2017; 317(4); 371-378.
2 Welsh JB, et al. Diabetes Technol Ther 2019;21(3):128-32.

BRIEF SAFETY STATEMENT: Available by prescription only. Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www. dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. © 2020 Dexcom Inc. All rights reserved. This product is covered by U.S. patent.